CD274 and neoplasm: Gunda et al. provided evidence for the justification for combining PD-L1 and lenvatinib in ATC using an ATC immunocompetent mice model [63]: lenvatinib caused a noticeable rise in tumor-associated macrophages and tumor-infiltrating immune cells, as well as a noticeable rise in peripheral and tumoral myeloid derived suppressor cells (PMN-MDSC), which together showed dramatic alterations in the immune microenvironment.